Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited is a global generic and specialty pharmaceutical manufacturer headquartered in Israel, with significant operations in the United States and Europe. The company is widely researched by investors interested in the generic drug sector, which serves as a lower-cost alternative to branded medications and represents a substantial portion of global pharmaceutical consumption.
Get a full AI research report on TEVA
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Teva Pharmaceutical Industries Limited do?
Teva generates revenue by developing, manufacturing, and distributing generic medicines across multiple dosage forms (tablets, injectables, inhalants, patches) and specialty branded products in CNS, respiratory, oncology, and other therapeutic areas. The company also operates an active pharmaceutical ingredients (API) business, provides contract manufacturing services, and maintains an out-licensing platform. Its portfolio includes branded products such as COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and AUSTEDO (tardive dyskinesia), alongside a vast generic drug catalog.
Bull case
- ✓Gross margin of 53.5% demonstrates pricing power and operational efficiency in manufacturing, typical of established generic players with scale.
- ✓Operating margin of 19.8% shows the company converts revenue to operating profit at a meaningful rate despite competitive generic pricing pressures.
- ✓Diversified revenue streams across generics, specialty branded drugs, and contract manufacturing reduce dependence on any single product or market segment.
- ✓Global geographic footprint spanning the United States, Europe, Israel, and international markets provides exposure to multiple healthcare systems and regulatory environments.
Bear case
- ✗Forward P/E of 51.1x and trailing P/E of 106.4x are substantially elevated, suggesting the market is pricing in significant future earnings growth that may not materialize.
- ✗Debt-to-equity ratio of 212.9% indicates very high financial leverage, limiting financial flexibility and increasing vulnerability to interest rate changes or revenue disruptions.
- ✗Net profit margin of only 2.9% means the company retains minimal profit per dollar of sales, leaving little cushion for operational challenges or pricing pressure.
- ✗Current ratio of 0.947 and quick ratio of 0.514 suggest potential near-term liquidity constraints, as current liabilities exceed current assets.
- ✗Zero dividend yield and zero payout ratio indicate the company is not returning capital to shareholders, potentially reflecting capital allocation toward debt service.
TEVA valuation & financial health
Teva's valuation presents a mixed picture. The forward P/E of 51.1x and trailing P/E of 106.4x are notably high relative to historical pharmaceutical averages, though the PEG ratio of 1.07 suggests some growth is priced in. The company's profitability metrics reveal strong gross margins (53.5%) and solid operating margins (19.8%), but net margins compress to just 2.9%, indicating significant non-operating expenses—likely driven by the 212.9% debt-to-equity ratio. Return on equity of 6.7% and return on assets of 5.4% are modest, reflecting the capital-intensive nature of the business and high leverage. Liquidity is a concern: the current ratio of 0.947 and quick ratio of 0.514 suggest the company may face near-term working capital pressures, though this is not uncommon in pharmaceutical manufacturing.
The bottom line
Teva operates a fundamentally sound generic and specialty pharmaceutical business with meaningful scale, diversification, and respectable operating margins. However, several factors warrant careful consideration: the elevated valuation multiples relative to earnings, the substantial debt burden that constrains financial flexibility, and the compressed net margins that leave limited room for error. Investors researching this stock should weigh the stability of generic drug demand and the company's branded product portfolio against the risks posed by high leverage, tight liquidity, and the sustainability of current profitability levels in a competitive market. Monitoring debt reduction progress, generic pricing trends, and specialty product performance would be key to assessing the company's trajectory.
Frequently asked questions
What does Teva Pharmaceutical Industries Limited do?
Teva develops, manufactures, and distributes generic medicines, specialty branded pharmaceuticals, and active pharmaceutical ingredients globally. The company serves multiple therapeutic areas including CNS, respiratory, and oncology, and also provides contract manufacturing services to other pharmaceutical companies.
Is TEVA a good stock to research?
Teva is a legitimate research subject for investors interested in the generic pharmaceutical sector, given its scale and diversified product portfolio. However, potential investors should carefully evaluate the high valuation multiples, significant debt load, and tight liquidity metrics before forming conclusions.
What are Teva's main revenue sources?
Revenue comes from generic medicines (the largest segment), specialty branded products like COPAXONE and AJOVY, active pharmaceutical ingredients, contract manufacturing services, and an out-licensing platform for products licensed to other companies.
Is TEVA overvalued?
The forward P/E of 51.1x and trailing P/E of 106.4x are elevated relative to many pharmaceutical peers, though the PEG ratio of 1.07 suggests some growth expectations are embedded in the price. Valuation assessment depends on individual assumptions about future earnings growth and risk tolerance.
What are the main risks for TEVA shareholders?
Key risks include high financial leverage (debt-to-equity of 212.9%), tight liquidity (current ratio below 1.0), compressed net margins (2.9%), and exposure to generic drug pricing pressure. Additionally, the elevated valuation multiples leave limited margin for disappointment in earnings.
Does Teva pay a dividend?
No, Teva currently has a dividend yield of 0% and a payout ratio of 0%, meaning the company does not distribute dividends to shareholders. This reflects a capital allocation strategy focused on debt management and reinvestment.
Research TEVA with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.